司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批

华尔街见闻05-21

替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

嗣舒
05-22
嗣舒
Share your opinion about this news…

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437446249?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/83f07867b8f6f3f3fcb868d0fc0fa6be","is_english":false,"pubTime":"2024-05-21 15:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2437446249","market":"us","top_or_hot":-1,"title":"司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批","media":"华尔街见闻","content":"<div>\n<p>替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3715379\">Source Link</a>\n\n</div>\n","source":"wallstreetcn_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-21 15:32 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3715379><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3715379\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://wallstreetcn.com/articles/3715379","article_id":"2437446249","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/83f07867b8f6f3f3fcb868d0fc0fa6be"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3715379","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2437446249","pubTimestamp":1716276750,"columns":[],"sourceInfo":{"source_id":"wallstreetcn_hot_news","name":"华尔街见闻"},"weMediaInfo":null,"summary":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。","collect":0,"end_time":0,"defaultTopTitle":"wallstreetcn.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LLY":"礼来"},"translate_title":"Semaglutide \"upgraded version\" is here! Eli Lilly Tilpoetide Injection Approved in China","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/ac46f8ec454b8429ed752c918acd6d5e","symbols_score_info":{"LLY":1},"content_text":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，研究表明GIP可以减少食物摄入、增加能量消耗，从而减轻体重。当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。值得一提的是，替尔泊肽能产生比有”减肥神药”之称的司美格鲁肽更好的减肥效果。相关研究数据表明表明，穆峰达5mg、10mg受试者体重平均降低7.8 kg、10.3 kg，司美格鲁肽1mg组平均降低6.2kg。去年，替尔泊肽获FDA批准用于慢性体重管理，以及体重相关合并症，如高血压、血脂异常、2型糖尿病、阻塞性睡眠呼吸暂停或心血管疾病，商品名为Zepbound。目前替尔泊肽减重适应症上市申请也获药监局受理，正在审评中。此外，减肥药大卖也在显著推升礼来业绩，Zepbound上市首季销售额超预期，完整季度就贡献5.17亿美元销售额，超出分析师预期的4.18亿美元。公司同时将全年营收指引上调20亿美元。此前有行业分析师预测，替尔泊肽可能成为有史以来最畅销的药物之一，年销售额将突破500亿美元，将超过诺和诺德的司美格鲁肽药物Ozempic和Wegovy。目前礼来市值达7443亿美元，高于标普成分股中的特斯拉、沃尔玛，为全球市值最高的药企。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":308452813885640,"gmtCreate":1716327705420,"gmtModify":1716329540126,"author":{"id":"4115205500438802","authorId":"4115205500438802","name":"嗣舒","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4115205500438802","idStr":"4115205500438802"},"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/308452813885640","repostId":2437446249,"repostType":2,"repost":{"id":"2437446249","kind":"news","pubTimestamp":1716276750,"share":"https://ttm.financial/m/news/2437446249?lang=&edition=fundamental","pubTime":"2024-05-21 15:32","market":"us","language":"zh","title":"司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2437446249","media":"华尔街见闻","summary":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。","content":"<html><head></head><body><blockquote><p><strong>替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。</strong></p></blockquote><p>减肥药赛道竞争愈发激烈，<a href=\"https://laohu8.com/S/LLY\">礼来</a>穆峰达在华获批上市。</p><p>5月21日，国家药监局官网显示<strong>，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。</strong></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/77c56e4948bd5b7d48cfb79e511e5054\" tg-width=\"716\" tg-height=\"211\"/></p><p>替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，研究表明GIP可以减少食物摄入、增加能量消耗，从而减轻体重。<strong>当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。</strong></p><p><strong>值得一提的是，替尔泊肽能产生比有”减肥神药”之称的司美格鲁肽更好的减肥效果。</strong></p><p>相关研究数据表明表明，穆峰达5mg、10mg受试者体重平均降低7.8 kg、10.3 kg，司美格鲁肽1mg组平均降低6.2kg。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1cd6a793f8dc35a0cc9d5e0520c59d39\" tg-width=\"756\" tg-height=\"372\"/></p><p>去年，替尔泊肽获FDA批准用于慢性体重管理，以及体重相关合并症，如高血压、血脂异常、2型糖尿病、阻塞性睡眠呼吸暂停或心血管疾病，商品名为Zepbound。<strong>目前替尔泊肽减重适应症上市申请也获药监局受理，正在审评中。</strong></p><p>此外，减肥药大卖也在显著推升礼来业绩，Zepbound上市首季销售额超预期，完整季度就贡献5.17亿美元销售额，超出分析师预期的4.18亿美元。公司同时将全年营收指引上调20亿美元。</p><p>此前有行业分析师预测，替尔泊肽可能成为有史以来最畅销的药物之一，年销售额将突破500亿美元，将超过<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>的司美格鲁肽药物Ozempic和Wegovy。</p><p>目前礼来市值达7443亿美元，高于标普成分股中的<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>、<a href=\"https://laohu8.com/S/WMT\">沃尔玛</a>，为全球市值最高的药企。</p></body></html>","source":"wallstreetcn_hot_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-21 15:32 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3715379><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3715379\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/83f07867b8f6f3f3fcb868d0fc0fa6be","relate_stocks":{"LLY":"礼来"},"source_url":"https://wallstreetcn.com/articles/3715379","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2437446249","content_text":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，研究表明GIP可以减少食物摄入、增加能量消耗，从而减轻体重。当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。值得一提的是，替尔泊肽能产生比有”减肥神药”之称的司美格鲁肽更好的减肥效果。相关研究数据表明表明，穆峰达5mg、10mg受试者体重平均降低7.8 kg、10.3 kg，司美格鲁肽1mg组平均降低6.2kg。去年，替尔泊肽获FDA批准用于慢性体重管理，以及体重相关合并症，如高血压、血脂异常、2型糖尿病、阻塞性睡眠呼吸暂停或心血管疾病，商品名为Zepbound。目前替尔泊肽减重适应症上市申请也获药监局受理，正在审评中。此外，减肥药大卖也在显著推升礼来业绩，Zepbound上市首季销售额超预期，完整季度就贡献5.17亿美元销售额，超出分析师预期的4.18亿美元。公司同时将全年营收指引上调20亿美元。此前有行业分析师预测，替尔泊肽可能成为有史以来最畅销的药物之一，年销售额将突破500亿美元，将超过诺和诺德的司美格鲁肽药物Ozempic和Wegovy。目前礼来市值达7443亿美元，高于标普成分股中的特斯拉、沃尔玛，为全球市值最高的药企。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437446249"}